Advanced Therapy RegulationHearing, Brussels May 11, 2006
Dr.Andreas ReimannCEO, Mukoviszidose e.V. (German Cystic Fibrosis Association)
Vice-Chairman, ACHSE e.V. (German Alliance for Rare Diseases)Member of the Board of Directors, European Organisation for Rare Diseases
(EURORDIS)
2
Statement on potential Conflicts of Interest• Mukoviszidose e.V. (Bonn)
- Financed up to 4% in total by funds provided by approx. 25 pharmaceutical companies
- Mainly financed by private donors not related to health industry
• ACHSE e.V. (Berlin)- Financed mainly (approx.90%) by funds provided by
institutional or corporate donors not related to the health industry
• EURORDIS (Paris)- Financed up to 16% by funds provided by the members
of the EURORDIS Round Table of Companies and 37% provided as an unrestricted grant from the French Muscular Dystrophy (AFM) association. Remainder mainly financed through EC-project grants (31 %) and members (3 %).
3
Disclaimer• Unless mentioned specifically, the views
expressed in that presentation represent the author‘s personal opinion and may or may not represent the views of Mukoviszidose e.V., ACHSE or EURORDIS.
• EURORDIS has commented on a previous draft in 2005 and this contribution is included in that presentation, where applicable.
• Neither of the organisations has issued a consensus document on the use of human embryonic stem cells.
• This disclaimer should, however, not be understood in a way that the views expressed in that presentation are reflecting an isolated position only.
4
Why patients with rare diseases hope for Advanced Therapies (AT)
• 30 mio citizens of Europe affected by one of the 5-6000 rare diseases
• 80% are of genetic background, most affect children
• For the majority of rare diseases, no cure is available today
• Patients put therefore considerable hope on new therapies including but not limited to ATs
• We realize that nobody can for sure say when and whether these therapies will be helpful for specific diseases
5
General positive comments
• Because patients put considerable hope on Advanced Therapies, the scope and content of the EC proposal is very much welcomed
• Central Evaluation and composition of CAT (patient representation, expertise) is welcomed because of the need to evaluate and to monitor both safety and efficacy of ATs
• Incentives for applicants are appropriate• The need for „sufficient flexibility“ is well
recognized
6
Critical issues - general
• No support for the commercialisation of unmodified human tissues and cells, therefore donation of tissues and cells must (rather than „should“) be unpaid and voluntary
• It is fine to exclude tailor-made products for single patients from need for registration, however, this must not become an easy way to evade the central registration
7
Critical issues – role of CAT
• Who provides the scientific advice to the applicants, the CAT or the CHMP/SAWP or both? (re: art.17.1)
• Can the CAT provide scientific advice to the applicant on its own right or only by request of CHMP?
• What happens if CAT scientific advice on development is not in accordance with CHMP?
• What happens if CAT and CHMP are in disagreement with regard to MA? Is the CAT a scientific body only or will it have the opportunity to appeal to the EC? (re: art.9.4)
8
Critical issues – traceability and post-authorisation follow-up• Long-term follow up of both safety and efficacy
must be mandatory to establish a „learning system“. Provisions needs to be in place to ensure so.
• Therefore, relevant data (clinical trials, observational studies, registries, spontaneous reporting) on PM-surveillance (safety and efficacy) must be reported systematically to the EMEA, where a public risk management system needs to be established.
• Traceability to the end-user must be established independent of the MA-holder.
• Art.16 should therefore be amended accordingly
9
• Because of its skills, and of its harmonised procedures, this structure would allow for a better follow-up of these products and the constitution of a precious public registry on safety and efficacy of advanced therapies products.
• This long term follow-up and data collection would certainly benefit the development of the whole sector and would enhance public support and confidence towards advanced therapies.
Central Data Base
10
Points to consider
• Concept of rec.6 and art.28 is welcome, i.e. central evaluation but „opt-out“ option for MS if there exists a conflict with their national legislation or policy in using certain types of cells (e.g. human embryonic stem cells)
• That principle must be legally „water-tight“
11
Points to consider (cont‘)
• However, there is no need to include animal cells in that exceptional provision for ethical reasons
• The regulation should specifically exclude the evaluation and marketing-authorisation of techniques using genetic manipulation of germ-cells, reproductive cloning or human/animal chimaeras
12
German Cystic Fibrosis Associationwww.muko.info
European Organisation for Rare Diseaseswww.eurordis.org
German Rare Disease Alliance:Allianz Chronischer Seltener Erkrankungenwww.achse-online.de
Top Related